Reporting owner · CIK 0001973838

Gloria Melanie

Visual SEC Form 4 history across 1 companies, 1 transactions and 1 filings.

COOChief Operating OfficerImmunovant, Inc.
Open-market mix
Filings1Form 4 records
Buying$00 purchases
Selling$135K1 sales
Net value−$135KBuys minus sells
Companies11 securities
Most recentAug 20, 2026sale

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for this insider's their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.

Monthly open-market activity

Reported purchase and sale transaction counts

Buys Sells
530-3-51Aug 26

Net value flow

Buys minus sells

Aug 26
−$135K

Transaction texture

Ownership and ticket size

Average P/S size$135K
Median P/S size$135K
Direct1
Indirect0
Aug 20, 2026sale

Filing-only signals

Deterministic matches in this insider's history

Latest Form 4 facts

Quick context from source filings

Latest transaction

sale at Immunovant, Inc. on Aug 20, 2026 valued at $134,953.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Associated companies

Visual map of known reporting history

TickerInsiderRoleTypeSharesValueCodeSignals90d returnFiledTrans date
IMVTGloria Melanie
COO
sale3.05k-$13.4MS7.1%08/2108/20

Gloria Melanie Insider Activity FAQ

SEC Form 4 context

Who is Gloria Melanie?

Gloria Melanie is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001973838.

Which companies has Gloria Melanie reported transactions for?

Immunovant, Inc.

When was Gloria Melanie's latest insider buy?

No open-market insider purchase is available for this period.

When was Gloria Melanie's latest insider sale?

sale at Immunovant, Inc. on Aug 20, 2026 valued at $134,953.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.